{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+gel+%28combination%29&page=2", "query": { "intervention": "Placebo gel (combination)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+gel+%28combination%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+gel+%28combination%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T15:22:16.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02616614", "title": "Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Onexton", "type": "DRUG" }, { "name": "Clindamycin/benzoyl peroxide gel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Years to 40 Years" }, "enrollment_count": 862, "start_date": "2015-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2020-05-27", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616614" }, { "nct_id": "NCT05886660", "title": "Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Motion Sickness, Space", "Motion Sickness", "Sea Sickness" ], "interventions": [ { "name": "DPI-386 Nasal Gel", "type": "DRUG" }, { "name": "Placebo Nasal Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repurposed Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2022-01-21", "completion_date": "2024-09", "has_results": false, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05886660" }, { "nct_id": "NCT01471652", "title": "Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Fatigue Syndrome" ], "interventions": [ { "name": "Nutraceutical supplements", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "25 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2012-03", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2015-04-13", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471652" }, { "nct_id": "NCT00357994", "title": "Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Parkinson's Disease" ], "interventions": [ { "name": "Levodopa carbidopa intestinal gel (LCIG)", "type": "DRUG" }, { "name": "Placebo gel", "type": "DRUG" }, { "name": "Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets", "type": "DRUG" }, { "name": "Placebo (PBO) oral capsules", "type": "DRUG" }, { "name": "CADD-Legacy® 1400 ambulatory infusion pump", "type": "DEVICE" }, { "name": "PEG tube", "type": "DEVICE" }, { "name": "J-tube", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 36, "start_date": "2009-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2015-01-16", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 8, "location_summary": "Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00357994" }, { "nct_id": "NCT01318694", "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "ALV Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1081, "start_date": "2011-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 32, "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01318694" }, { "nct_id": "NCT01008111", "title": "Wound Healing of Incisional Wounds for Bilateral Hernia Repair", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Wound Healing" ], "interventions": [ { "name": "Dermabond", "type": "DRUG" }, { "name": "Hydrogen Peroxide Oxygen producing gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "5 Years", "sex": "ALL", "summary": "Up to 5 Years" }, "enrollment_count": 0, "start_date": "2009-10", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008111" }, { "nct_id": "NCT00002186", "title": "Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Herpes Simplex", "HIV Infections" ], "interventions": [ { "name": "Crofelemer", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shaman Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002186" }, { "nct_id": "NCT00841386", "title": "Treatment of Keratoconus Using Collagen Cross-Linking", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Keratoconus" ], "interventions": [ { "name": "Riboflavin-5-phosphate", "type": "DRUG" }, { "name": "Sham cross-linking", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "16 Years to 35 Years" }, "enrollment_count": 150, "start_date": "2008-09", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2009-02-11", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 2, "location_summary": "Amherst, New York • Buffalo, New York", "locations": [ { "city": "Amherst", "state": "New York" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00841386" }, { "nct_id": "NCT06361381", "title": "The Combined Effect of TENS and TaVNS on Pressure and Heat Pain Thresholds in Pain-Free Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)", "type": "DEVICE" }, { "name": "Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)", "type": "DEVICE" }, { "name": "Transcutaneous Electrical Nerve Stimulation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Hartford", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 30, "start_date": "2024-04-01", "completion_date": "2024-10-20", "has_results": false, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 1, "location_summary": "West Hartford, Connecticut", "locations": [ { "city": "West Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06361381" }, { "nct_id": "NCT01183169", "title": "Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 459, "start_date": "2010-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-08-25", "last_synced_at": "2026-10-04T15:22:16.629Z", "location_count": 18, "location_summary": "San Diego, California • Ventura, California • Bradenton, Florida + 13 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183169" } ] }